SCHEMBL10209101

SCHEMBL10209101

CC(C)(C)OC(=O)NCC1CCCC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.54
KMT2A Q03164 1/20 0.50
DRD2 P14416 2/20 0.49
ACACB O00763 5/20 0.48
CTSS P25774 1/20 0.48
CTSK P43235 1/20 0.48
ACACA Q13085 3/20 0.46
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP3 P08254 1/20 0.44
MMP9 P14780 1/20 0.44
MMP8 P22894 1/20 0.44
CA9 Q16790 1/20 0.44
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL60318 0.98 EPHX1 (0.56) EPHX1KMT2ADRD2ACACBCTSS
SCHEMBL228180 0.96 EPHX1 (0.50) EPHX1KMT2ADRD2ACACBCTSS
Bicarbonate SCHEMBL5780143 0.95 EPHX1 (0.54) EPHX1KMT2ADRD2ACACBCTSS
Acetic Acid SCHEMBL3275951 0.93 EPHX1 (0.52) EPHX1KMT2ADRD2ACACBCTSS
SCHEMBL3942686 0.92 KMT2A (0.56) EPHX1KMT2ADRD2ACACBCTSS
SCHEMBL3816616 0.92 KMT2A (0.56) EPHX1KMT2ADRD2ACACBCTSS
SCHEMBL4377073 0.92 KMT2A (0.56) EPHX1KMT2ADRD2ACACBCTSS
SCHEMBL190838 0.92 KMT2A (0.56) EPHX1KMT2ADRD2ACACBCTSS
SCHEMBL17109668 0.91 EPHX1 (0.50) EPHX1KMT2ADRD2ACACBCTSS
SCHEMBL6647123 0.89 EPHX1 (0.48) EPHX1KMT2ADRD2ACACBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107208-A1 COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS THE METHODIST HOSPITAL (US) 2026-05-21 WO disclosed
WO-2023017152-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2023-02-16 WO disclosed
CN-107417707-A 1H pyrazolos [3,4 b] pyridine and its treatment use 萨穆梅德有限公司 2017-12-01 CN disclosed
CN-104271133-B 1H-pyrazolo [3,4-b ] pyridines and therapeutic uses thereof 萨穆梅德有限公司 2017-10-13 CN disclosed
CN-106892916-A The indazole inhibitors and its treatment use of WNT signal paths 萨穆梅德有限公司 2017-06-27 CN disclosed
CN-104202984-B Indazole inhibitors of the WNT signaling pathway and therapeutic uses thereof 萨穆梅德有限公司 2017-04-05 CN disclosed
CN-103254190-B Heteroaryl substituted pyrrolo-[2,3-b] pyridine and pyrrolo-[2,3-b] pyrimidine as Janus inhibitors of kinases 因塞特控股公司 2016-12-07 CN disclosed
US-9206142-B2 Anilinopiperazine derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2015-12-08 US disclosed
CN-104271133-A 1H-pyrazolo [3,4-b ] pyridines and therapeutic uses thereof SAMUMED LLC 2015-01-07 CN disclosed
CN-104202984-A Indazole inhibitors of the WNT signaling pathway and therapeutic uses thereof SAMUMED LLC 2014-12-10 CN disclosed
US-8835461-B2 Substituted 3-hydroxy-4-pyridone derivative SHIONOGI & CO., LTD. (JP) 2014-09-16 US disclosed
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC 2012-12-27 US disclosed
US-20120058989-A1 ANTIBACTERIAL FLUOROQUINOLONE ANALOGS ACHAOGEN, INC. (US) 2012-03-08 US disclosed
US-20120022255-A1 SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022255-A1 SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE ENDOD1, CNBP, DPP4 EPHX1 758/4885KMT2A 3094/4885DRD2 3718/4885
US-20120058989-A1 ANTIBACTERIAL FLUOROQUINOLONE ANALOGS RECQL, BLVRB, NQO2 EPHX1 2310/4885KMT2A 4780/4885DRD2 198/4885
US-20120328691-A1 ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF MAPK15, CDK15, MAPKAPK5 EPHX1 3954/4885KMT2A 3820/4885DRD2 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.